Clinical Trial Search

Primary: Overall Survival: Time From Randomization to Date of Death — 21.2; 21.5 Months — p=0.9009

Primary: The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24) — 69.7; 66.2; 60.6; 66.7…

Primary: Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation — 0; 0; 0; 5 Participants

Primary: Mean Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) at Week 4 — -13.3; -17.0; -12.7 Units on a scale — p=0.8590

Primary: Intraoperative Duration — 22.6; 13.0; 25.0; 28.6 minutes

Primary: Change From Baseline Trough in 24-Hour Weighted Mean FEV1 on Treatment Day 84 — 0.114; 0.142 Liters — p=0.267

Primary: Number of Participants With Treatment Related Adverse Events. — 44 participants

Primary: The Primary Outcome Measure Was a Patient Global Assessment of Change (PGIC) Scale. — 3.3 units on a scale

Primary: Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and…

Primary: Time to First Event (Death, Stroke, Major Bleed) — 0.0785; 0.0987; 0.1542; 0.1820 cumulative probability of event — p=0.14

Primary: The Success Rate — 95.2 percentage of participants

Primary: Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Week 24 — 72.4; -6.9 Units on a scale

Primary: Number of Participants With Treatment Related Adverse Events. — 29 participants

Primary: Overall Cleansing Level at Colonoscopy by Ottawa Bowel Preparation Scale — 2.58; 3.22; 2.97 units on a scale — p=0.435

Primary: Change in Glycosylated Hemoglobin A1c (HbA1c) From Baseline to Week 24 — -0.66; -0.47 Percentage